15 September 2021 | Wednesday | News
BMG Pharma – a biotech and B2B company headquartered in Milan with its chemical plant in Torviscosa (Italy) that exports its medical products to more than 80 countries – has signed a development and commercial agreement with HTL, a leading biotech and industrial player in the development and production of innovative, pharmaceutical-grade biopolymers. With this agreement, HTL will exclusively develop, scale-up, and supply a high-grade functional injectable Hyaluronic Acid based active ingredient, Sodium Hyaluronate Lipoate Formate (SHLF), for a major part of BMG Pharma’s products.
The agreement will allow BMG Pharma to develop, register, and launch its injectable grade Sodium Hyaluronate Lipoate Formate (SHLF) product platform in Europe, the US, and Asia. SHLF’s properties including improved resistance to enzymatic degradation, self-crosslinking properties, and elastic modulus are of great interest in dermo-aesthetic and osteoarthritis medicine. SHLF is also considered for therapeutic solutions in ophthalmology and osteoarthritis.
“SHLF has been developed in our R&D labs and allows us to further leverage the therapeutical potential of hyaluronan for several medical applications. We are very excited and proud of the long-term partnership with HTL, which is a recognized international leader in R&D and manufacturing for Medical Grade Biopolymers" - comments Marco Mastrodonato, CEO and Co-Founder of BMG Pharma, adding: "The agreement with HTL will let us enforce our commitment in this area and develop products that can bring advantages not only in aesthetic medicine but also to patients with degenerative joint or ophthalmological diseases."
The agreement with HTL is part of the commitment to innovation and technological research pursued by the Italian company, with its leading position in R&D. BMG Pharma will be able to develop for the first time at a global level, new formulations of injectable products with high standards of quality, stability, and safety.
“Developing and producing innovative, pharmaceutical-grade biopolymers for international leaders aiming at improving the lives of their patients, represent the very core of our activity.” explains Charles Ruban, HTL’s Deputy CEO. “This is why we are particularly delighted to have the opportunity to collaborate with BMG Pharma and mobilize our unique expertise and know-how to produce the unique functionalized biopolymers of uncompromised quality its patients deserve.”